key: cord-0859925-h758j653 authors: Manzia, Tommaso Maria; Gazia, Carlo; Lenci, Ilaria; Angelico, Roberta; Toti, Luca; Monaco, Andrea; Anselmo, Alessandro; Baiocchi, Leonardo; Grossi, Paolo; Tisone, Giuseppe title: Liver transplantation performed in a SARS‐CoV‐2 positive hospitalized recipient using a SARS‐CoV‐2 infected donor date: 2021-03-17 journal: Am J Transplant DOI: 10.1111/ajt.16548 sha: 0bdb6dd59b9e6334e597d02a4aecb47777dc08e1 doc_id: 859925 cord_uid: h758j653 The coronavirus disease 2019 (COVID‐19) is a novel infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). COVID‐19 currently affected more than 108 million people worldwide with a fatality rate of 2.2%. Herein, we report the first case of liver transplantation (LT) performed with a liver procured from a SARS‐CoV‐2 positive donor. The recipient was a 35‐year‐old SARS‐CoV‐2 positive female patient affected by severe end‐stage HBV‐HDV‐related liver disease (model of end‐stage liver disease = 32) who had neutralizing SARS‐CoV‐2 antibodies (titers 1:320) at time of LT. The LT was successful, and the graft is functioning two months after surgery. The recipient cleared the SARS‐CoV‐2 infection 1 month after LT. The current case shows that the prompt use of SARS‐CoV‐2 infected liver donors offers an invaluable life‐saving opportunity for SARS‐CoV‐2 positive wait‐listed patients who developed neutralizing SARS‐CoV‐2 antibodies. clinical research/practice, donors and donation: extended criteria, infection and infectious agents -viral, infectious disease, liver transplantation/hepatology, organ procurement and allocation SARS-CoV-2 recipient who developed neutralizing SARS-CoV-2 antibodies. A 33-year-old female (weight: 48 kg; height: 160 cm; body mass index: 19) patient with end-stage HBV-HDV-related cirrhosis, with a biochemical Model for End-stage Liver Disease (MELD) score of 30, was listed for LT in November 2020, at the Tor Vergata University Transplant Center in Rome, Italy. Five days after listing, the patient underwent a routine SARS-CoV-2 nasopharyngeal swab, and all 2019 nCoV genes (E/N/S) were detected at real-time polymerase chain reaction (RT-PCR), indicating an ongoing infection according to the detected cycle thresholds (Ct) 6 ( Table 1) . The patient had no respiratory symptoms, but the chest CT scan showed features of ground glass pneumonia. The patient was thus suspended from the LT waiting list and transferred to a nonsur- The day after listing, a liver graft from a 65-year-old brain-dead female donor (weight: 65 kg; height: 165 cm; body mass index: 24) was offered for our patient. The donor risk index (DRI) 8 was 1.94 and the graft-to-recipient weight ratio was 2.8. During the donor screening procedures, the bronchoalveolar lavage (BAL) for SARS-CoV-2 resulted positive for all three genes (RT-PCR, Allplex SARS-CoV-2 Assay Seegene; gene E Ct = 24; gene S Ct = 27; gene N Ct = 24). The donor had no previous medical history of COVID-19. Due to the severely impaired clinical status of our recipient, implying an exceedingly high risk of death, we decided to accept the organ offer and to proceed with the LT. The preallocation score to predict survival outcome following liver transplantation (P-SOFT) was 12 and the balance of risk score (BAR) was 10, 9,10 corresponding to an estimated prediction of 6-and 12-month survival of 92% and 86%, respectively. All of the personnel involved in the LT were adequately equipped with surgical caps, protective N95 filtering and surgical facemasks, isolation gowns, and double gloves. The LT recipient was provided with surgical cap and surgical mask. None of the involved personnel ever tested positive for SARS-CoV-2 after LT. The intraoperative BAL for detection of for SARS-CoV-2 was positive ( Table 1 ). The patient remained stable intraoperatively, and the surgical procedure was completed uneventful. An induction therapy with 5000 IU of hepatitis B immunoglobulin was ad- The Our recipient had a good neutralizing antibodies titer (1:320) on the day of transplant which was protective against a superinfection. In addition, despite the prolonged positivity of the RT-PCR, our patient underwent LT a month after the first detection of SARS-CoV-2 infection (specifically with a high Ct value for all genes) ( Table 1) . According to recently published papers, this positivity probably does not reflect an ongoing active infection but simply the amplification of nonreplicating virus. 12, 13 For this reason, we believe that transplanting patients with longlasting asymptomatic infection with high neutralizing antibodies titer is a reasonable option for urgent candidates. Once the MELD score had reached 32, the patient was further prioritized in the transplant list by granting an urgency status at the national level, which allowed to be successfully transplanted the following day. This case report shows that detection of SARS-CoV-2 positivity in waitlisted patients with end-stage liver disease who present neutralizing SARS-CoV-2 antibodies and normal respiratory function should no longer be considered a contraindication to LT. In our patient, the MELD-estimated 3-month risk of death while remaining on the waiting list was more than 50%; hence, the patient had much less life expectancy compared to a post-LT 6-month survival rate greater than 90%, according to P-SOFT and BAR. 9,10 It should also be noted that in Italy the overall risk of death due to COVID-19 is 3.5%, 4 The COVID-19 outbreak in Italy: initial implications for organ transplantation programs A novel coronavirus from patients with pneumonia in China Clinical features of patients infected with 2019 novel coronavirus in Wuhan World Health Organization. Weekly Epidemiological and Operational updates Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Correlation of SARS-CoV-2 nucleocapsid antigen and RNA concentrations in nasopharyngeal samples from children and adults using an ultrasensitive and quantitative antigen assay Characteristics associated with liver graft failure: the concept of a donor risk index Are there better guidelines for allocation in liver transplantation? A novel score targeting justice and utility in the model for end-stage liver disease era Value of the preoperative SOFT-score, P-SOFT-score, SALT-score and labMELD-score for the prediction of short-term patient and graft survival of high-risk liver transplant recipients with a pre-transplant labMELD-score ≥30 Multicenter study of age, frailty, and waitlist mortality among liver transplant candidates Predicting infectious SARS-CoV-2 from diagnostic samples Virological assessment of hospitalized patients with COVID-2019 Awareness and Impact of non-pharmaceutical interventions during coronavirus disease 2019 pandemic in renal transplant recipients Protective role of tacrolimus, deleterious role of age and comorbidities in liver transplant recipients with Covid-19: results from the ELITA/ELTR multi-center European study Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study COVID-19: consider cytokine storm syndromes and immunosuppression The arrival of Sputnik V Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Covid-19 vaccines: delivering protective immunity